Please assess the completion status of the following clinical trial:

Trial Title: Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven prostate adenocarcinoma.~* Planned prostatectomy with lymph node dissection.~* Intermediate to high-risk disease (as determined by elevated Prostate-specific antigen (PSA) \[PSA\>10\], T-stage \[T2b or greater\], Gleason score \[Gleason score \> 6\] or other risk factors).~* Diagnostic CT or MRI as part of the PET study or performed within one month of PSMA PET.~* Karnofsky performance status of greater than 50 (or Eastern Cooperative Oncology Group (ECOG) /World Health Organization (WHO) equivalent).~* Age \> 18.~* Ability to understand a written informed consent document, and the willingness to sign it.~Exclusion Criteria:~* Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam.~* Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy.~* Including focal ablation techniques (HiFu).~* Androgen deprivation therapy or other neoadjuvant treatments prior to PET imaging and surgery.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ga-68 labeled PSMA-11 PET (Type: EXPERIMENTAL): PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.

Based on this trial design, predict the completion outcome and termination type (if applicable).